Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 80 clinical trials
Featured trial
  • 13 views
  • 08 Feb, 2022
  • 20 locations
Featured trial
A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy. Clinical trial NCT02319837, MDV3100-13.

A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing

  • 107 views
  • 02 Sep, 2021
  • 1 location
Featured trial
A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance (ENACT). NCT02799745, 9785-MA-1010.

This is a multicenter, randomized, open label exploratory study, conducted in the US and Canada, evaluating the efficacy and safety of enzalutamide for extension of time to prostate cancer

  • 80 views
  • 02 Sep, 2021
  • 1 location
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

be nine cohorts in this study: Cohort A will receive pembrolizumab + olaparib, Cohort B will receive pembrolizumab + docetaxel + prednisone, Cohort C will receive pembrolizumab + enzalutamide, Cohort

enzalutamide
gonadotropin releasing hormone
dexamethasone 8 mg
prostate adenocarcinoma
bone scan
  • 3 views
  • 06 Jun, 2022
  • 32 locations
  • 17 views
  • 13 Jul, 2022
  • 85 locations
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH)

The purpose of this study is to evaluate the efficacy and safety of [Lu-177]-PNT2002 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with androgen receptor axis-targeted therapy (ARAT).

  • 0 views
  • 16 Jun, 2022
  • 48 locations
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC who have progressed on prior abiraterone by

  • 0 views
  • 10 Aug, 2022
  • 15 locations
Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer (ENZA-p)

This phase 2 randomised clinical trial will investigate the activity and safety of adding Lu-PSMA to enzalutamide in patients with metastatic castrate resistant prostate cancer (mCRPC) not

enzalutamide
direct bilirubin
prostate adenocarcinoma
bone scan
bone metastases
  • 1 views
  • 26 Mar, 2022
  • 13 locations
Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

Asymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after treatment with combination or sequential ADT + Abi will be treated on a randomized, open label study to determine if sequential treatment with high dose T and Enza will improve primary and secondary objectives vs. continuous Enza …

  • 2 views
  • 10 Aug, 2022
  • 1 location
Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC

CORT125281 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) to identify a recommended dose (RD) for Phase 2 studies.

enzalutamide
gonadotropin releasing hormone
prostate adenocarcinoma
hormone releasing
luteinizing hormone
  • 145 views
  • 26 Feb, 2022
  • 7 locations